<VariationArchive VariationID="428937" VariationName="NM_003002.4(SDHD):c.388dup (p.Ala130fs)" VariationType="Duplication" Accession="VCV000428937" Version="6" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-06-23" DateCreated="2017-07-01" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="420758" VariationID="428937">
      <GeneList>
        <Gene Symbol="SDHD" FullName="succinate dehydrogenase complex subunit D" GeneID="6392" HGNC_ID="HGNC:10683" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>11q23.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="112086873" stop="112095794" display_start="112086873" display_stop="112095794" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="111957570" stop="111966517" display_start="111957570" display_stop="111966517" Strand="+" />
          </Location>
          <OMIM>602690</OMIM>
          <Haploinsufficiency last_evaluated="2021-08-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHD">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-08-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=SDHD">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_003002.4(SDHD):c.388dup (p.Ala130fs)</Name>
      <CanonicalSPDI>NC_000011.10:112094876:GG:GGG</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>11q23.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="112094876" stop="112094877" display_start="112094876" display_stop="112094877" variantLength="1" positionVCF="112094876" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="111965600" stop="111965601" display_start="111965600" display_stop="111965601" variantLength="1" positionVCF="111965600" referenceAlleleVCF="T" alternateAlleleVCF="TG" />
      </Location>
      <ProteinChange>A91fs</ProteinChange>
      <ProteinChange>H82fs</ProteinChange>
      <ProteinChange>A130fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.112094878dup" Assembly="GRCh38">
            <Expression>NC_000011.10:g.112094878dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.111965602dup" Assembly="GRCh37">
            <Expression>NC_000011.9:g.111965602dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012337.3" sequenceAccession="NG_012337" sequenceVersion="3" change="g.13032dup">
            <Expression>NG_012337.3:g.13032dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276503.2" sequenceAccession="NM_001276503" sequenceVersion="2" change="c.243dup">
            <Expression>NM_001276503.2:c.243dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263432.1" sequenceAccession="NP_001263432" sequenceVersion="1" change="p.His82fs">
            <Expression>NP_001263432.1:p.His82fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276504.2" sequenceAccession="NM_001276504" sequenceVersion="2" change="c.271dup">
            <Expression>NM_001276504.2:c.271dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001263433.1" sequenceAccession="NP_001263433" sequenceVersion="1" change="p.Ala91fs">
            <Expression>NP_001263433.1:p.Ala91fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001276506.2" sequenceAccession="NM_001276506" sequenceVersion="2" change="c.*86dup">
            <Expression>NM_001276506.2:c.*86dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_003002.4" sequenceAccession="NM_003002" sequenceVersion="4" change="c.388dup" MANESelect="true">
            <Expression>NM_003002.4:c.388dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_002993.1" sequenceAccession="NP_002993" sequenceVersion="1" change="p.Ala130fs">
            <Expression>NP_002993.1:p.Ala130fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_077060.2" sequenceAccession="NR_077060" sequenceVersion="2" change="n.477dup">
            <Expression>NR_077060.2:n.477dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_9" sequenceAccession="LRG_9">
            <Expression>LRG_9:g.13032dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_9t1" sequenceAccession="LRG_9t1">
            <Expression>LRG_9t1:c.388dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_9p1" sequenceAccession="LRG_9p1" change="p.Ala130fs">
            <Expression>LRG_9p1:p.Ala130fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA645369586" DB="ClinGen" />
        <XRef Type="rs" ID="1131691063" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_003002.4(SDHD):c.388dup (p.Ala130fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000492485" Version="3">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-07-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_003002.4(SDHD):c.388dup (p.Ala130fs) AND multiple conditions" Accession="RCV003766764" Version="1">
        <ClassifiedConditionList TraitSetID="73586">
          <ClassifiedCondition DB="MedGen" ID="C1847319">Carney-Stratakis syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="CN166604">Cowden syndrome 3</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1868633">Paragangliomas with sensorineural hearing loss</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0031511">Pheochromocytoma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-09-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-05" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2017-07-01" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12114404</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17848412</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20208144</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21348866</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25758995</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="73586" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3796" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Chromaffinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Medullary paraganglioma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Chromaffin cell tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Pheochromocytoma</ElementValue>
                <XRef ID="Pheochromocytoma/5718" DB="Genetic Alliance" />
                <XRef ID="HP:0002666" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0008233" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHB-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">SDHD-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15105" />
                <XRef ID="15105" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">KIF1B-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">VHL-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">TMEM127-Related Susceptibility to Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">RET-Related Pheochromocytoma</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Neuroendocrine and Adrenal Tumors, 2023</CitationText>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C0031511" DB="MedGen" />
              <XRef ID="MONDO:0008233" DB="MONDO" />
              <XRef Type="MIM" ID="171300" DB="OMIM" />
              <XRef Type="primary" ID="HP:0002666" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="17663" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cowden syndrome 3</ElementValue>
                <XRef ID="MONDO:0014045" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">CWS3</ElementValue>
              </Symbol>
              <XRef ID="201" DB="Orphanet" />
              <XRef ID="CN166604" DB="MedGen" />
              <XRef ID="MONDO:0014045" DB="MONDO" />
            </Trait>
            <Trait ID="3265" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Carney-Stratakis syndrome</ElementValue>
                <XRef ID="MONDO:0011740" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastrointestinal stromal tumor</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and GIST</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney-Stratakis dyad of paraganglioma and gastric stromal sarcoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Carney dyad</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Paraganglioma and gastric stromal sarcoma</ElementValue>
                <XRef ID="Paraganglioma+and+gastric+stromal+sarcoma/5577" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10643" />
                <XRef ID="10643" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Soft Tissue Sarcoma, 2024</CitationText>
              </Citation>
              <XRef ID="97286" DB="Orphanet" />
              <XRef ID="C1847319" DB="MedGen" />
              <XRef ID="MONDO:0011740" DB="MONDO" />
              <XRef Type="MIM" ID="606864" DB="OMIM" />
            </Trait>
            <Trait ID="8850" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Paragangliomas with sensorineural hearing loss</ElementValue>
              </Name>
              <XRef ID="C1868633" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="8525925" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2024-02-28">
        <ClinVarSubmissionID localKey="4900793|MedGen:C1847319;C1868633;C0031511;C3554516" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004570856" DateUpdated="2024-02-28" DateCreated="2024-02-28" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12114404</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21348866</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25758995</ID>
          </Citation>
          <Comment>This variant disrupts a region of the SDHD protein in which other variant(s) (p.Leu139Pro) have been determined to be pathogenic (PMID: 12114404, 21348866, 25758995). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This sequence change results in a frameshift in the SDHD gene (p.Ala130Glyfs*61). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 30 amino acid(s) of the SDHD protein and extend the protein by 30 additional amino acid residues. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SDHD-related conditions. ClinVar contains an entry for this variant (Variation ID: 428937). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.111965600_111965601insG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1847319" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1868633" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0031511" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3554516" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1132248" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2017-07-01">
        <ClinVarSubmissionID localKey="a96918|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000581224" DateUpdated="2024-05-01" DateCreated="2017-07-01" Type="SCV" Version="6" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-07-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17848412</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20208144</ID>
          </Citation>
          <Comment>The c.388dupG pathogenic mutation, located in coding exon 4 of the SDHD gene, results from a duplication of G at position 388, causing a translational frameshift with a predicted alternate stop codon (p.A130Gfs*61). This frameshift occurs at the 3' terminus of SDHD, alters the final 30 amino acids of the protein, and results in the elongation of the protein by 30 residues. It has been identified in multiple unrelated patients with paragangliomas and pheochromocytomas (Ambry internal data). In addition, a close nucleotide change, c.386dupT, which results in the same stop codon, was reported in multiple probands with personal and family histories of paragangliomas (Lima J et al. J. Clin. Endocrinol. Metab. 2007 Dec;92(12):4853-64; Hermsen MA et al. Cell. Oncol. 2010 Jan;32(4):275-83). Based on the available evidence, this alteration is interpreted as a disease-causing mutation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="SDHD" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_003002.2:c.388dupG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="8525925" TraitType="Disease" MappingType="XRef" MappingValue="C3554516" MappingRef="MedGen">
        <MedGen CUI="CN166604" Name="Cowden syndrome 3" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8525925" TraitType="Disease" MappingType="XRef" MappingValue="C1847319" MappingRef="MedGen">
        <MedGen CUI="C1847319" Name="Carney-Stratakis syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1132248" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8525925" TraitType="Disease" MappingType="XRef" MappingValue="C1868633" MappingRef="MedGen">
        <MedGen CUI="C1868633" Name="Paragangliomas with sensorineural hearing loss" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8525925" TraitType="Disease" MappingType="XRef" MappingValue="C0031511" MappingRef="MedGen">
        <MedGen CUI="C0031511" Name="Pheochromocytoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

